Evidence map›Paper›PMID 20507591›Full record

ArticleRetrovirology2010

Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies.

Kathryn H Richards, Marlén Mi Aasa-Chapman, Aine McKnight, Paul R Clapham

Open access · goldAbstract readCase Reports
In one paragraph

Article in Retrovirology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. The HIV-1 env protein: a coat of many colors.Current HIV/AIDS reports · 2012
    Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Kathryn H RichardsProgram in Molecular Medicine and Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Biotech 2, 373 Plantation Street, Worcester, MA 01605, USA.
Marlén Mi Aasa-Chapman
Aine McKnight
Paul R Clapham
Queen Mary University of London · GBUniversity College London · GBUniversity of Leeds · GBUniversity of Massachusetts Chan Medical School · US

Funding

Variation in HIV-1 R5 Envs: Consequences for tropism, neutralization & vaccinesP01AI082274 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2013
$9.7M
HIV-1 tropism neuropathogenesis and therapyR01MH064408 · NIMH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CLAPHAM, PAUL R · 2001 to 2011
$3.5M
Tropism and transmissibility of HIV-1 envelopes in semenR01HD049273 · NICHD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CLAPHAM, PAUL R · 2005 to 2009
$1.3M
Medical Research Council G117/547NIAID NIH HHS P01 AI082274NICHD NIH HHS R01 HD049273NIMH NIH HHS R01 MH064408
6 · The paper itself

Abstract

HIV-1 R5 viruses vary widely in their capacity to infect primary macrophages. R5 macrophage-tropism is associated with an increased envelope:CD4 affinity that partly results from an increased exposure of CD4 contact residues on gp120 and allows the use of low levels of CD4 for infection. The selective pressures in vivo that modulate R5 macrophage-tropism are not understood. It is possible that different R5 variants adapt for replication in either T-cells (high CD4) or in macrophages (low CD4). However, other selective pressures in vivo (e.g. neutralizing antibodies) may also impact R5 tropism. Here, we measured macrophage infectivity conferred by gp120 sequences amplified sequentially from subjects in London followed from the acute stage of infection. We report wide variation in the capacity of these envelopes to confer macrophage infection in the complete absence of both autologous and heterologous neutralizing antibodies. Our data show that the variation in macrophage tropism observed at early times cannot have been influenced by neutralizing antibodies.

Indexed as

Viral TropismAntibodies, NeutralizingCells, Culturedenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansLondonMacrophagesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID20507591
PMCPMC2890664
OpenAlexW2148001199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.